Search

Yashu Liu

from Tempe, AZ
Age ~38
Get Report
Related to:
Marta B Bill, 65Shuo Liu, 57Benjamin BencomoClaudia P ZapataA A, 57Fernando Rodriguez, 65Fabricio Zapata, 49Douglas A Warrington, 58
Connected to:
Abraham C Liu, 109Adele T Liu, 65Adi P Liu, 35Alan Y Liu, 39Albert Y Liu, 36Alen K Liu, 39Alma R Liu, 73Amanda T Liu, 54Ambrose M Liu, 52An P Liu, 59

Yashu Liu Phones & Addresses

  • 1522 E Southern Ave APT 2082, Tempe, AZ 85282
  • Hawthorne, NY
  • Ann Arbor, MI
  • Mesa, AZ

Work

Company: Sri international, 2011 Position: Research scientist

Education

School / High School: Peking University 2003 Specialities: Ph.D. in Proteomics

Skills

mass spectrometry • liquid chromatography • protein characterization • method development and validation • GLP experience • writing SOP

Languages

English

Interests

Healthcare Informatics • Civil Rights and Social Action • Computer Vision Etc • Education • Machine Learning • Environment • Science and Technology • Human Rights • Data Mining • Arts and Culture • Health

Industries

Higher Education

Resumes

Resumes

Yashu Liu Photo 1

Visiting Student

View page
Location:
Tempe, AZ
Industry:
Higher Education
Work:
Arizona State University since Aug 2011
Graduate Research Assistant
Arizona State University Jun 2011 - Aug 2011
Student Worker
Education:
Arizona State University 2010 - 2010
Skills:
Machine Learning
Matlab
Data Mining
Computer Science
Algorithms
C++
Computer Vision
Python
C
Graphics
Programming
Research
Bioinformatics
Latex
C#
Mathematics
Sql
Data Analysis
Interests:
Healthcare Informatics
Civil Rights and Social Action
Computer Vision Etc
Education
Machine Learning
Environment
Science and Technology
Human Rights
Data Mining
Arts and Culture
Health
Languages:
English
Yashu Liu Photo 2

Yashu Liu Harrisonburg, VA

View page
Work:
SRI International,

2011 to 2000
Research Scientist
University of Michigan, Ann Arbor
Ann Arbor, MI
2008 to 2011
Researcher Fellow
Education:
Peking University
2003 to 2008
Ph.D. in Proteomics
Peking University
1999 to 2003
B.S. in Polymer Science and engineering
Skills:
mass spectrometry, liquid chromatography, protein characterization, method development and validation, GLP experience, writing SOP

Business Records

Name / Title
Company / Classification
Phones & Addresses
Yashu Liu
Director
US China Business & Culture Inc
Management Consulting Services
116 John St, New York, NY 10038
(212) 695-4973

Publications

Us Patents

Anti-Muc16 Antibodies, Antibody-Drug Conjugates, And Bispecific Antigen-Binding Molecules That Bind Muc16 And Cd3, And Uses Thereof

View page
US Patent:
20200317810, Oct 8, 2020
Filed:
Jun 26, 2020
Appl. No.:
16/913154
Inventors:
- Tarrytown NY, US
Eric Smith - New York NY, US
Marcus Kelly - New York NY, US
Jessica R. Kirshner - New York NY, US
Sandra Coetzee - White Plains NY, US
Alison Crawford - Dobbs Ferry NY, US
Thomas Nittoli - Paul River NY, US
Yashu Liu - Tarrytown NY, US
International Classification:
C07K 16/30
C07K 16/46
A61K 39/395
C07K 16/28
C07K 16/44
A61K 47/68
G01N 33/574
Abstract:
Mucin 16 (MUC16) is highly expressed in ovarian cancer and expression on cancer cells is shown to protect tumor cells from the immune system. The present invention provides novel full-length human IgG antibodies that bind to human andMUC16 (monospecific antibodies). The present invention also provides novel bispecific antibodies (bsAbs) that bind to both MUC16 and CD3 and activate T cells via the CD3 complex in the presence of MUC16-expressing tumors. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human and monkey CD3, and a second antigen-binding molecule that specifically binds human and monkey MUC16. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing MUC16. The bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an upregulated or induced MUC16-targeted immune response is desired and/or therapeutically beneficial. For example, the bispecific antibodies of the invention are useful for the treatment of various cancers, including ovarian cancer. The present invention also includes anti-MUC16 antibody drug conjugates which inhibit tumor growth in vivo. In some embodiments, the anti-MUC16 antibodies are useful in diagnostic methods for identifying the presence of MUC16 in tissue and/or plasma samples.

Human Antibodies To Bet V 1 And Methods Of Use Thereof

View page
US Patent:
20180346555, Dec 6, 2018
Filed:
May 31, 2018
Appl. No.:
15/994294
Inventors:
- Tarrytown NY, US
Andrew J. Murphy - Croton-on-Hudson NY, US
Ashok T. Badithe - Basking Ridge NJ, US
Vishal Kamat - Bergenfield NJ, US
Yashu Liu - White Plains NY, US
International Classification:
C07K 16/16
A61P 37/08
Abstract:
Provided herein are antibodies that bind Fagales allergens, Fagales related allergens, birch pollen, or Bet v 1, compositions comprising the antibodies, nucleic acids encoding the antibodies, and methods of using the antibodies. According to certain embodiments, the antibodies are fully human monoclonal antibodies that bind to Bet v 1. The antibodies are useful for binding Bet v 1 in vivo, thus preventing binding of the allergen to pre-formed IgE on the surface of mast cells or basophils. In doing so, the antibodies act to prevent the release of histamine and other inflammatory mediators from mast cells and/or basophils, thus ameliorating the untoward response to the Fagales allergens in sensitized individuals.

Assays For Screening Activity Of Modulators Of Members Of The Hydroxysteroid (17-Beta) Dehydrogenase (Hsd17B) Family

View page
US Patent:
20180291422, Oct 11, 2018
Filed:
Mar 6, 2018
Appl. No.:
15/913366
Inventors:
- Tarrytown NY, US
David Esopi - Tarrytown NY, US
Jesper Gromada - Tarrytown NY, US
Jorge Haller - Tarrytown NY, US
Yashu Liu - Tarrytown NY, US
Andrew Murphy - Tarrytown NY, US
William Olson - Tarrytown NY, US
International Classification:
C12Q 1/32
C12Q 1/66
C12N 9/04
C12N 9/96
G01N 33/74
Abstract:
Screening methods as well as kits for identifying modulators of hydroxysteroid (17-beta) dehydrogenase (HSD17B) family member proteins, such as HSD17B13, are provided. The methods comprise screening molecules for their capacity to modulate the HSD17B family member protein, including inhibiting the HSD17B family member protein, as measured by substrate depletion, product concentration from the HSD17B family member protein substrate conversion or NADH concentration, levels of labeled substrate, luciferin light emission, or combinations thereof. Inhibitors of HSD17B family member proteins identified through the screening methods may be used to treat liver diseases, disorders, or conditions in which the HSD17B family member protein plays a role.

Anti-Muc16 Antibodies, Antibody-Drug Conjugates, And Bispecific Antigen-Binding Molecules That Bind Muc16 And Cd3, And Uses Thereof

View page
US Patent:
20180118848, May 3, 2018
Filed:
Sep 22, 2017
Appl. No.:
15/713578
Inventors:
- Tarrytown NY, US
Eric Smith - New York NY, US
Marcus Kelly - New York NY, US
Jessica R. Kirshner - New York NY, US
Sandra Coetzee - White Plains NY, US
Alison Crawford - Dobbs Ferry NY, US
Thomas Nittoli - Pearl River NY, US
Yashu Liu - Tarrytown NY, US
International Classification:
C07K 16/30
G01N 33/574
C07K 16/28
A61K 47/68
Abstract:
Mucin 16 (MUC16) is highly expressed in ovarian cancer and expression on cancer cells is shown to protect tumor cells from the immune system. The present invention provides novel full-length human IgG antibodies that bind to human and MUC16 (monospecific antibodies). The present invention also provides novel bispecific antibodies (bsAbs) that bind to both MUC16 and CD3 and activate T cells via the CD3 complex in the presence of MUC16-expressing tumors. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human and monkey CD3, and a second antigen-binding molecule that specifically binds human and monkey MUC16. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing MUC16. The bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an upregulated or induced MUC16-targeted immune response is desired and/or therapeutically beneficial. For example, the bispecific antibodies of the invention are useful for the treatment of various cancers, including ovarian cancer. The present invention also includes anti-MUC16 antibody drug conjugates which inhibit tumor growth in vivo. In some embodiments, the anti-MUC16 antibodies are useful in diagnostic methods for identifying the presence of MUC16 in tissue and/or plasma samples.

Anti-Muc16 Antibodies, Antibody-Drug Conjugates, And Bispecific Antigen-Binding Molecules That Bind Muc16 And Cd3, And Uses Thereof

View page
US Patent:
20180112001, Apr 26, 2018
Filed:
Sep 22, 2017
Appl. No.:
15/713574
Inventors:
- Tarrytown NY, US
Eric Smith - New York NY, US
Marcus Kelly - New York NY, US
Jessica R. Kirshner - New York NY, US
Sandra Coetzee - White Plains NY, US
Alison Crawford - Dobbs Ferry NY, US
Thomas Nittoli - Pearl River NY, US
Yashu Liu - Tarrytown NY, US
International Classification:
C07K 16/28
C07K 16/30
A61K 47/68
Abstract:
Mucin 16 (MUC16) is highly expressed in ovarian cancer and expression on cancer cells is shown to protect tumor cells from the immune system. The present invention provides novel full-length human IgG antibodies that bind to human and MUC16 (monospecific antibodies). The present invention also provides novel bispecific antibodies (bsAbs) that bind to both MUC16 and CD3 and activate T cells via the CD3 complex in the presence of MUC16-expressing tumors. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human and monkey CD3, and a second antigen-binding molecule that specifically binds human and monkey MUC16. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing MUC16. The bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an upregulated or induced MUC16-targeted immune response is desired and/or therapeutically beneficial. For example, the bispecific antibodies of the invention are useful for the treatment of various cancers, including ovarian cancer. The present invention also includes anti-MUC16 antibody drug conjugates which inhibit tumor growth in vivo. In some embodiments, the anti-MUC16 antibodies are useful in diagnostic methods for identifying the presence of MUC16 in tissue and/or plasma samples.

Predicting Drug-Drug Interactions And Specific Adverse Events

View page
US Patent:
20170177803, Jun 22, 2017
Filed:
Dec 21, 2015
Appl. No.:
14/976002
Inventors:
- Armonk NY, US
Yashu Liu - Tempe AZ, US
Ping Zhang - White Plains NY, US
International Classification:
G06F 19/00
Abstract:
The present invention provides methods, systems and devices for drug-drug interaction and adverse event analysis. Chemical structures for one or more pairs of drugs are obtained from at least one of a user and a database. A chemical fingerprint is generated for each drug of the one or more pairs of drugs based on the chemical structure of the drug. Drug-drug interaction prediction is performed for each pair of drugs based on the chemical fingerprints. Adverse event prediction is performed based on the predicted drug-drug interaction for the one or more pairs of drugs.

Anti-Prlr Antibodies And Uses Thereof

View page
US Patent:
20150056222, Feb 26, 2015
Filed:
Oct 31, 2014
Appl. No.:
14/530265
Inventors:
- Tarrytown NY, US
Gavin THURSTON - Briarcliff Manor NY, US
Jessica R. KIRSHNER - New York NY, US
Marcus P. KELLY - New York NY, US
Thomas NITTOLI - Pearl River NY, US
Frank J. DELFINO - Poughquag NY, US
William C. OLSON - Yorktown Heights NY, US
Yashu LIU - Tarrytown NY, US
International Classification:
A61K 47/48
C07K 16/30
C07K 16/28
US Classification:
4241781, 5303879, 5303917, 5303919
Abstract:
The present invention provides antibodies that bind to prolactin receptor (PRLR) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human PRLR with high affinity. In certain embodiments, the invention includes antibodies that bind PRLR and block prolactin-mediated cell signaling. In other embodiments, the invention includes antibodies that bind PRLR but do not block prolactin-mediated cell signaling. According to certain embodiments, the invention includes antibodies that bind to the first fibronectin-like type III domain of the extracellular domain of PRLR. The antibodies of the invention may be fully human antibodies. The invention includes anti-PRLR antibodies conjugated to a cytotoxic agent, radionuclide, or other moiety detrimental to cell growth or proliferation. The antibodies of the invention are useful for the treatment of various cancers as well as other PRLR-related disorders. The present invention also includes antibody drug conjugates comprising an antibody or antigen-binding fragment thereof that specifically binds a class I cytokine receptor, wherein the antibody or antigen-binding fragment thereof is conjugated to a cytotoxic agent.
Control profile
Yashu Liu from Tempe, AZ, age ~38 Get Report